Insulin: Research, Benefits & Safety

Quick facts

Class: Peptide hormone (51 amino acids)
Brands/analogs: Humulin, NovoLog, Lantus, and many more
Approved for: Type 1 and type 2 diabetes
Administration: Injection (and inhaled/pump forms)
Status: FDA-approved, foundational therapy
Class: Peptide hormone (51 amino acids)
Discovered: 1921; first therapeutic use 1922
Main risk: Hypoglycemia (low blood sugar)
Status: WHO Essential Medicine; prescription

Key takeaways

Insulin is an essential, life-sustaining peptide hormone and the prototypical peptide drug, not a research chemical.
It lowers blood glucose by activating the insulin receptor, promoting cellular glucose uptake and energy storage.
It is the cornerstone of type 1 diabetes care and is also used in type 2 diabetes and certain emergencies.
Hypoglycemia is the most important risk; therapy must be individualized and medically supervised.
Engineered analogs vary in speed and duration to better mimic natural insulin patterns.

Overview

Insulin is a 51-amino-acid peptide hormone produced by the beta cells of the pancreatic islets of Langerhans. It is the central regulator of blood glucose and one of the most clinically important peptides in medicine. Discovered in 1921 and first used therapeutically in 1922, insulin transformed type 1 diabetes from a fatal condition into a manageable one and remains essential, life-sustaining therapy for millions worldwide.

Structurally, insulin consists of two chains, an A-chain and a B-chain, linked by disulfide bonds. It is the prototypical peptide drug: the first protein to be sequenced, the first to be produced by recombinant DNA technology, and the template against which much of peptide pharmacology is understood. Modern therapy uses recombinant human insulin and engineered analogs.

Insulin is a foundational medicine listed by the World Health Organization as essential, not a research chemical or experimental compound. It is prescribed and manufactured to strict pharmaceutical standards and used under medical supervision for diabetes management.

How it works

Insulin lowers blood glucose by binding to the insulin receptor, a tyrosine kinase found on muscle, fat, and liver cells. Receptor activation triggers signaling cascades that promote the uptake of glucose from the blood into cells, largely by recruiting glucose transporters to the cell surface in muscle and fat tissue.

Beyond glucose uptake, insulin promotes the storage of energy. It stimulates glycogen synthesis in the liver and muscle, suppresses the liver's production of new glucose, promotes fat storage, and supports protein synthesis. In effect, it signals the body's transition from a fasting to a fed metabolic state.

Engineered analogs modify the natural sequence to change how quickly insulin is absorbed and how long it acts. Rapid-acting analogs are designed to act quickly around meals, while long-acting and ultra-long-acting analogs provide a steadier background level. These pharmacokinetic differences let clinicians tailor therapy to mimic the body's normal insulin patterns.

Clinical evidence

Insulin's clinical evidence base is among the largest and longest-standing in medicine, spanning a century of use. Landmark long-term studies such as the Diabetes Control and Complications Trial in type 1 diabetes and the UK Prospective Diabetes Study in type 2 diabetes established that intensive glucose control reduces the risk of long-term complications affecting the eyes, kidneys, and nerves.

Insulin is the cornerstone of treatment for type 1 diabetes, where the body produces little or no insulin, and it is also used in type 2 diabetes when other therapies are insufficient. It is essential in certain emergencies, such as diabetic ketoacidosis, and may be used during pregnancy-related diabetes.

Comparative research continues to evaluate analog versus human insulin, different delivery methods such as pumps and continuous glucose monitoring, and newer ultra-long-acting formulations. The overall goal across this evidence is balancing effective glucose control against the risk of hypoglycemia.

Dosing & side effects

Insulin therapy is highly individualized and must be managed by a healthcare professional. This article does not provide dosing figures. Requirements vary widely between people and over time, influenced by diet, activity, illness, weight, and the specific formulation used. Self-adjusting insulin without medical guidance can be dangerous.

The most important and common risk is hypoglycemia, or low blood glucose, which can cause shakiness, confusion, sweating, and in severe cases loss of consciousness or seizures. Recognizing and promptly treating low blood sugar is a core part of safe insulin use. Other effects can include weight gain and reactions at injection sites.

Insulin is most often given by subcutaneous injection or insulin pump, with rapid-acting forms also used intravenously in hospital settings. Proper storage, rotation of injection sites, and coordination with food and activity are essential. People using insulin typically receive structured education on monitoring and managing their glucose.

Legal status

Insulin is an approved prescription medicine worldwide and is regulated as a pharmaceutical by agencies such as the US Food and Drug Administration and the European Medicines Agency. Both human insulin and its analogs are manufactured under strict quality standards, and many formulations are available, including biosimilar products.

It is included on the World Health Organization Model List of Essential Medicines, reflecting its status as a fundamental, life-saving therapy. In most countries it requires a prescription, though access rules and over-the-counter availability of older formulations vary by jurisdiction.

Affordability and access have been significant policy issues, particularly regarding pricing. Insulin is not a gray-market research chemical; it is a mainstream, tightly regulated medicine that should only be obtained through legitimate pharmacies and used under professional care.

Frequently asked questions

Is insulin a research chemical?

No. Insulin is a fully approved, essential prescription medicine with a century of clinical use. It is manufactured to strict pharmaceutical standards and is fundamentally different from unapproved research compounds.

What is the main risk of insulin therapy?

Hypoglycemia, or low blood glucose, is the most common and important risk. It can range from mild symptoms like shakiness and sweating to severe events including confusion, seizures, or loss of consciousness, and requires prompt treatment.

What is the difference between human insulin and analogs?

Human insulin matches the natural sequence, while analogs are engineered with small modifications that change how fast they are absorbed and how long they act, allowing therapy to better mimic the body's normal insulin patterns.

Is insulin used for both type 1 and type 2 diabetes?

Yes. It is essential and life-sustaining in type 1 diabetes, where the body makes little or no insulin. In type 2 diabetes it is used when other treatments are not sufficient to control blood glucose.

Why is insulin usually injected rather than taken as a pill?

As a peptide, insulin would be broken down by digestion if swallowed. It is therefore given by subcutaneous injection or pump, and intravenously in hospital settings, to reach the bloodstream intact.

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

Related guides: Semaglutide · Tirzepatide · Tesamorelin · All Weight Loss & Metabolic peptides →

Insulin